In Pfizer’s first-quarter 2017 financial report, total revenue was down 2 percent year over year. The company also reported three discontinued pipeline projects.
AbbVie Inc. reported a larger-than-expected first-quarter 2017 profit, lifted by demand for the company’s flagship drug Humira.
As AstraZeneca faces declining revenue in 2017 from the loss of patents and the challenge of generic drugs, the company culled two drugs from its pipeline.
Princeton, N.J.-based CRO Covance plans to shutter its lab in Evansville, Ind., in summer 2017. More than 100 staffers are expected to be laid off.
Novartis reported better-than-expected first-quarter 2017 profits with CEO Joe Jimenez remaining confident the Swiss drugmaker would return to growth in 2018.
Biogen Inc.’s first-quarter 2017 profit blew past analysts’ estimates, helped by higher-than-expected sales of its recently launched spinal muscular atrophy drug Spinraza.
Johnson & Johnson reported disappointing pharmaceutical and consumer product sales for first-quarter 2017 as revenue missed analyst estimates.
Sanofi expected 2017 EPS to be stable or slightly lower after its fourth-quarter 2016 results were affected by an increase in taxes and one-off charges.
Merck & Co. Inc. reported better-than-expected U.S. quarterly sales for its key cancer drug Keytruda and forecast largely in-line 2017 results.
Shares of Bone Therapeutics dropped slightly after the company announced a change in leadership and ended plans to hold a clinical trial in the United States.
Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.
While there were definitely positive items in Biogen’s third-quarter 2016 report, the company also threw in what almost seemed like an afterthought – it was no longer developing amiselimod (MT-1303).
Abbott Laboratories reported a quarterly profit that edged past estimates as strength in its medical devices business more than offset a decline in its nutrition unit.
Novo Nordisk cut its forecast for full-year 2016 profit growth and said it expected tough competition in the United States to pressure prices in 2017.
Pfizer Inc. reported better-than-expected second-quarter 2016 results, but revenue from its branded patent-protected medicines brought disappointment.
Sanofi’s quarterly sales and profit fell despite double-digit growth at biotech arm Genzyme as the diabetes division came under sustained U.S. pricing pressure.
Bristol-Myers Squibb reported disappointing 2Q 2016 sales of its Yervoy melanoma treatment.
Celgene Corp. exceeded expectations for second-quarter 2016 earnings on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines.
Along with its dismal half-year financial reports, UK-based AstraZeneca announced it was halting six pipeline programs.
Eli Lilly reported better-than-expected second-quarter 2016 sales and predicted average annual revenue growth of at least 5 percent through the end of the decade.